November 2004 - Volume 44 - Issue : Journal of Cardiovascular Pharmacology

Journal Logo

November 2004 - Volume 44 - Supplement 1
pp: xiii-xiv,S1-S496

PDF Only



PDF Only


In Vivo Imaging of Cardiovascular Endothelin Receptors Using the Novel Radiolabelled Antagonist [18F]-SB209670 and Positron Emission Tomography (microPET)

Johnström, Peter; Fryer, Tim D.; Richards, Hugh K.; More

Journal of Cardiovascular Pharmacology. 44:S34-S38, November 2004.

Chronic Administration of an Endothelin-A Receptor Antagonist Improves Exercise Capacity in Rats with Myocardial Infarction-induced Congestive Heart Failure

Miyauchi, Takashi; Fujimori, Akira; Maeda, Seiji; More

Journal of Cardiovascular Pharmacology. 44:S64-S67, November 2004.

Inhibition of Both Neutral Endopeptidase and Endothelin-Converting Enzyme by SLV306 Reduces Proteinuria and Urinary Albumin Excretion in Diabetic Rats

Thöne-Reinke, Christa; Simon, Katja; Richter, Claus-Michael; More

Journal of Cardiovascular Pharmacology. 44:S76-S79, November 2004.

STRIDE 1: Effects of the Selective ETA Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension that meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials

Langleben, David; Brock, Tommy; Dixon, Richard; More

Journal of Cardiovascular Pharmacology. 44:S80-S84, November 2004.

Endothelin-A Receptor Antagonism Promotes Decreased Vasodilation but has no Differential Effect on Coronary Artery Compliance in Hypertensive Patients

Kyriakides, Zenon; Kyrzopoulos, Stamatis; Paraskevaidis, Ioannis; More

Journal of Cardiovascular Pharmacology. 44:S85-S88, November 2004.

Changes of Vasoregulatory Gene Expression Following Hepatic Ischemia/Reperfusion and Treatment with Endothelin-A Receptor Blockade

Uhlmann, Dirk; Gaebel, Gabor; Teupser, Daniel; More

Journal of Cardiovascular Pharmacology. 44:S100-S102, November 2004.

Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor

Spinella, Francesca; Rosanò, Laura; Elia, Giacomo; More

Journal of Cardiovascular Pharmacology. 44:S140-S143, November 2004.

Effects of Medium-chain Triglyceride (MCT) Application to SHR on Cardiac Function, Hypertrophy and Expression of Endothelin-1 mRNA and other Genes

Shimojo, Nobutake; Miyauchi, Takashi; Iemitsu, Motoyuki; More

Journal of Cardiovascular Pharmacology. 44:S181-S185, November 2004.

Endogenous Bradykinin Suppresses Myocardial Fibrosis through the Cardiac-generated Endothelin System Under Chronic Angiotensin-converting Enzyme Inhibition in Heart Failure

Fujii, Masanori; Wada, Atsuyuki; Ohnishi, Masato; More

Journal of Cardiovascular Pharmacology. 44:S346-S349, November 2004.

YM598, an Orally Active ETA Receptor Antagonist, Ameliorates the Progression of Cardiopulmonary Changes and Both-side Heart Failure in Rats with Cor Pulmonale and Myocardial Infarction

Fujimori, Akira; Miyauchi, Takashi; Sakai, Satoshi; More

Journal of Cardiovascular Pharmacology. 44:S354-S357, November 2004.

Changes of Endothelin-1 and Big Endothelin-1 Levels and Action Potential Duration during Myocardial Ischemia-reperfusion in Dogs with and without Ventricular Fibrillation

Vágó, Hajnalka; Soós, Pál; Zima, Endre; More

Journal of Cardiovascular Pharmacology. 44:S376-S379, November 2004.